Instituto do Cancer do Estado de Sao Paulo

São Paulo, São Paulo 01246-000

0 studies enrolling now · 4 studies all time

What they study most

Advanced Cholangiocarcinoma, Biochemically Recurrent Prostate Cancer, Cancer, FGFR2 Gene Rearrangements, Solid Tumors Harboring NTRK Fusion

Studies at this site

• Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer — Running, not enrolling
• A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies — Running, not enrolling
• A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors — Completed
• Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements — Stopped early